Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

45.60USD
4:00pm EDT
Change (% chg)

$1.01 (+2.27%)
Prev Close
$44.59
Open
$44.70
Day's High
$45.96
Day's Low
$44.20
Volume
47,127
Avg. Vol
94,053
52-wk High
$47.39
52-wk Low
$17.14

Latest Key Developments (Source: Significant Developments)

Loxo Oncology reports completion of clinical trial enrollment for larotrectinib NDA primary efficacy analysis
Tuesday, 21 Feb 2017 06:45am EST 

Loxo Oncology Inc : Loxo Oncology announces completion of clinical trial enrollment for larotrectinib nda primary efficacy analysis . Loxo Oncology Inc - company expects to report top-line data for NDA dataset in second half of 2017 .Loxo Oncology- expects to submit a new drug application in late 2017 or early 2018, and European marketing authorisation application in 2018.  Full Article

Loxo Oncology prices follow-on offering of common stock
Thursday, 5 Jan 2017 06:45am EST 

Loxo Oncology Inc : Loxo Oncology prices follow-on offering of common stock .Says public offering of 3.87 million common shares priced at $31.00per share.  Full Article

Loxo Oncology Q2 net loss per share $0.77
Wednesday, 3 Aug 2016 06:45am EDT 

Loxo Oncology Inc : Loxo oncology announces second quarter 2016 financial results . Qtrly net loss per share $0.77 . Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S .Continues to expect cash burn of $48 to $52 million in 2016.  Full Article

Loxo Oncology's LOXO-101 wins FDA's breakthrough therapy status
Wednesday, 13 Jul 2016 09:13am EDT 

Loxo Oncology Inc : Loxo Oncology Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For LOXO 101 .Remain on track to provide an enrollment update regarding loxo-101 phase 2 trial in second half of 2016.  Full Article

Aisling Capital III reports 18.6 pct stake in Loxo Oncology
Friday, 27 May 2016 04:17pm EDT 

Loxo Oncology Inc :Aisling Capital III, LP reports a stake of 18.6% in Loxo Oncology Inc as of May 17, 2016 - SEC filing.  Full Article

Loxo Oncology prices follow-on offering of common stock
Wednesday, 11 May 2016 07:34pm EDT 

Loxo Oncology Inc :Prices follow-on offering of common stock.  Full Article

Loxo Oncology to offer common stock
Wednesday, 11 May 2016 04:00pm EDT 

Loxo Oncology Inc :Loxo oncology announces proposed public offering of common stock.  Full Article

Loxo Oncology, Inc announces EMA orphan drug designation granted to LOXO-101 for treatment of soft tissue sarcoma
Friday, 15 Jan 2016 06:45am EST 

Loxo Oncology, Inc:Announces EMA Orphan Drug Designation granted to Loxo-101 for treatment of soft tissue sarcoma.  Full Article

Loxo Oncology prices follow-on offering of common stock
Wednesday, 11 Nov 2015 07:00pm EST 

Loxo Oncology:Says pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $26.50 per share.Gross proceeds to Loxo Oncology from this offering are expected to be approximately $66.3 million.Loxo Oncology intends to use the net proceeds from this offering for general corporate purposes.  Full Article

Loxo Oncology announces proposed public offering of common stock
Tuesday, 10 Nov 2015 04:00pm EST 

Loxo Oncology Inc:Commenced an underwritten public offering of up to 2,000,000 shares of its common stock.Intends to use the net proceeds from this offering for general corporate purposes.  Full Article

More From Around the Web

BRIEF-Loxo Oncology announces collaboration with Ventana Medical Systems

* Loxo Oncology announces larotrectinib pan-trk ihc companion diagnostic collaboration with Ventana Medical Systems, Inc., a member of the Roche Group